Beam Therapeutics

Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Beam Therapeutics excels in base editing therapies, poised for growth

Beam Therapeutics showcased strong performance in trials and technology development, positioning itself as a leader in base editing therapies.
While facing challenges in clinical translation and regulatory landscapes, Beam's focus on innovative solutions presents growth opportunities in gene editing.
Overall, Beam's financial strength, promising data, and strategic vision offer a solid foundation for future success in the biotech industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 59.09% and 69.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates

Advancing Pipeline of Wholly Owned Base Editing Therapeutics with Four Development-stage Programs

Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones

Today, we are putting Beam Therapeutics back in the spotlight after an initial article on this gene editing name last summer. Beam Therapeutics' stock has sunk by a third since that avoid recommendation, but the shares have recently been upgraded by several analyst firms.

Beam Therapeutics: An Upgraded View

Intellia Therapeutics

The two clinical-stage gene-editing companies have good long-term prospects.

Better Buy: Beam Therapeutics or Intellia Therapeutics?

CAMBRIDGE, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the SVB Securities Virtual Global Biopharma Conference on Tuesday, February 14, 2023, at 8:40 a.m. ET.

Beam Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

Cellectis SA

CRISPR Therapeutics

Editas Medicine

Sangamo Therapeutics

Verve Therapeutics

CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis.

7 CRISPR Stocks With the Best Long-Term Potential

Roku

Shopify

Vanguard Growth ETF

These growth stocks have more room to run.

5 Top Stocks for February

Maravai LifeSciences Holdings

Novavax

These beaten-down stocks could be poised for major rebounds.

3 Great Growth Stocks Down 20% or More to Buy Now

MercadoLibre

SoundHound AI Inc

Aggressive investors should check out these stocks.

A New Bull Market Is Coming: 3 Stocks That Could Skyrocket

BEACON Trial of BEAM-101 in Sickle Cell Disease Ongoing with Data from Multiple Patients Expected in 2024; Expansion Phase Initiation Expected in 2023

Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones

AbCellera Biologics

AST SpaceMobile

JFrog

HashiCorp

Maxar Technologies

MongoDB

UiPath

Planet Labs

Prime Medicine Inc

Rocket Lab USA

Sumo Logic

Tesla

While others flock to safety, should you do the opposite? Some of the best times to invest in highly speculative names are when no one wants them, as long as the reasons are macro and not company or industry specific.

10 Potential 10x Return Stocks For The Next 10 Years

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, Jan. 9, 2023 at 11:15 a.m. PT in San Francisco.

Beam Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Exact Sciences

Block

Teladoc

Zoom Video

Twilio

Cathie Wood makes big bets on potential huge winners. But Ark Invest's top 10 holdings, including Tesla and Roku, have tumbled in 2022.

Cathie Wood Has Bet Big On These 10 Stocks; Here's How They're Performing

Agios Pharmaceuticals

Atara Biotherapeutics

The attraction of all three biotech stocks is their potential.

3 Under-the-Radar Biotech Stocks to Buy in 2022

Arista Networks

Broadcom

Daqo New Energy

Matson

Trane Technologies plc

The next big things for investors are always around the corner. As investors say goodbye to the 2022 bear market, we look forward to what could be an excellent 2023.

7 ‘Next Big Things' for Investors to Buy for 2023

Data from ESCAPE-1 and ESCAPE-2 Approaches to Be Presented During Poster Sessions at the 64th ASH Annual Meeting and Exposition Data from ESCAPE-1 and ESCAPE-2 Approaches to Be Presented During Poster Sessions at the 64th ASH Annual Meeting and Exposition

Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead of Autologous Transplant

Beam Therapeutics announced the recruitment of its first BEACON trial patient in the middle of November 2022. BEAM's announcement was followed by Editas Medicine's declaration of positive safety and efficacy data from its first two patients enrolled and treated under the Ruby trial.

Beam Therapeutics: Expected To Boost Pipeline Development Into 2023

The FDA lifts the clinical hold on BEAM's investigational new drug application for BEAM-201 to treat relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma. Stock up.

BEAM Up as FDA Lifts Clinical Hold on the IND for BEAM-201

Beam Ranked No. 4 in Large Companies Category, Marking Fourth Consecutive Year as Top Workplace in Massachusetts Beam Ranked No. 4 in Large Companies Category, Marking Fourth Consecutive Year as Top Workplace in Massachusetts

Beam Therapeutics Named to Boston Globe's Top Places to Work List for 2022

BioNTech SE

Vertex Pharmaceuticals

Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding around 0.5% on Thursday.

BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts - Beam Therapeutics (NASDAQ:BEAM), BioNTech (NASDAQ:BNTX)

CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold and cleared the Investigational New Drug (IND) application for BEAM-201 for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL)/T-cell lymphoblastic lymphoma (T-LL). BEAM-201 is a potent and specific anti-CD7, multiplex-edited, allogeneic chimeric antigen receptor T-cell development candidate.

Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201

Shares of Beam Therapeutics lost buying momentum in recent weeks. Gene-editing therapy stocks are out of favor.

Buy Beam Therapeutics For 2023

CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat during the BofA Securities 2022 Virtual Biotech SMID Cap Conference on Wednesday, December 7, 2022 at 2:55 p.m. ET.

Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference

BEAM-101 BEACON Trial Represents the First Clinical Trial of a Base Editor in the United States BEAM-101 BEACON Trial Represents the First Clinical Trial of a Base Editor in the United States

Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease

CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in the following upcoming investor conferences:

Beam Therapeutics to Participate in Upcoming Investor Conferences

News for Beam Therapeutics Stock (BEAM)